Promising Trial

PARP inhibitors finally have some proof, writes Derek Lowe at In the Pipeline. He notes that the drug class has had its ups and downs, as PARP inhibitors developed by various companies haven't always done well in trials — or even always been PARP inhibitors.

But Lowe reports that Tesaro announced yesterday that neraparib, which it licensed from Merck, has shown promising results in ovarian cancer.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Researchers have sequenced the northern white rhinoceros to gauge whether it could be brought back from the edge of extinction, the New York Times reports.

Bavaria expands its forensic genetic analyses to include DNA phenotyping, raising discrimination concerns.

Tufts University researchers found a role for miRNA in transmitting stress between generations, the Economist reports.

In Science this week: gut microbiome influences liver cancer growth, spread; and more.